HCID 178472925, 화합물 → HCID 178472926, 화합물
반응식
[CH2:1]([O:3][C:4](=[O:35])[CH2:5][NH:6][S:7]([C:10]1[S:11][C:12]([C:15]#[C:16][C:17]2[CH:34]=[N:33][C:20]3[N:21]=[C:22]([NH:26][C:27](=[O:32])[C:28]([CH3:31])([CH3:30])[CH3:29])[N:23]=[C:24]([OH:25])[C:19]=3[CH:18]=2)=[CH:13][CH:14]=1)(=[O:9])=[O:8])[CH3:2]>C(O)(=O)C.[Pt]=O>[CH2:1]([O:3][C:4](=[O:35])[CH2:5][NH:6][S:7]([C:10]1[S:11][C:12]([CH2:15][CH2:16][CH:17]2[CH2:34][NH:33][C:20]3[N:21]=[C:22]([NH:26][C:27](=[O:32])[C:28]([CH3:29])([CH3:30])[CH3:31])[N:23]=[C:24]([OH:25])[C:19]=3[CH2:18]2)=[CH:13][CH:14]=1)(=[O:8])=[O:9])[CH3:2]참가 물질
4
실험 절차
To a mixture of 150 mg of N-[5-(2-pivaloylamino-4-hydroxypyrido[2,3-d]pyrimidin-6-ylethynyl)thien-2-ylsulfonyl]glycine ethyl ester in 25 mL of glacial acetic acid was added 100 mg of platinum oxide. This mixture was stirred under hydrogen for 24 hours and an additional 100 mg of platinum oxide was added. The hydrogenation was resumed for another 24 hours and the reaction mixture was then filtered through Celite® and the filtrate concentrated in vacuo. The residue was flash chromatographed on silica gel using 3.5% CH3OH and chloroform to give 48 mg of N-{5-[2-(2-pivaloylamino-4-hydroxy-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl)-ethyl]thien-2-ylsulfonyl}glycine ethyl ester as a white solid. 1H NMR (300 MHz, DMSO-d6, δ1.10 (t, J=7 Hz, 3H), 1.17 (s, 9H), 1.62 (m, 3H), 1.90 (m, 1H), 2.52 (m, 1H), 2.91 (m, 3H), 3.25 (m, 1H), 3.68 (d, J=4.9 Hz, 2H), 3.97 (q, J=7 Hz, 2H), 6.45 (s, 1H), 6.92 (d, J=3.5 Hz, 1H, 7.38 (d, J=3.5 Hz, 1H), 8.31 (t, J=4.9 Hz, 1H).